financetom
Business
financetom
/
Business
/
What's Going On With LuxUrban Hotels (LUXH) Shares?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With LuxUrban Hotels (LUXH) Shares?
Jun 4, 2024 8:50 AM

LuxUrban Hotels Inc ( LUXH ) shares are trading lower by 10.6% to $0.28 during Tuesday's session, pulling back following earlier strength. The company announced that its Board of Directors has formed a Special Committee of independent directors to explore strategic initiatives aimed at maximizing shareholder value. 

The committee will evaluate various strategic transactions, including equity and debt financing, sales, mergers, acquisitions or other alternatives. No specific timeline has been set, and the company is not currently engaged in any transaction or has hired advisors for the committee’s work. 

Leonard Toboroff will chair the Special Committee. The company will only disclose updates if necessary or required by law. Elan Blutinger, Chairman of the Board, expressed confidence in the company’s innovative model and the committee’s alignment with shareholder interests. 

See Also: Dave Portnoy Blasts E*Trade Amid Roaring Kitty Ban Considerations

How To Buy LUXH Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in LuxUrban Hotels' ( LUXH ) case, it is in the Real Estate sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, LUXH has a 52-week high of $6.88 and a 52-week low of $0.24.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Plains All American Pipeline's Q3 Adjusted Net Income, Revenue Rise
Plains All American Pipeline's Q3 Adjusted Net Income, Revenue Rise
Nov 8, 2024
08:12 AM EST, 11/08/2024 (MT Newswires) -- Plains All American Pipeline ( PAA ) reported Q3 adjusted net income Friday of $0.37 per diluted unit, up from $0.35 a year earlier. Analysts surveyed by Capital IQ expected $0.31. Revenue for the quarter ended Sept. 30 was $12.74 billion, compared with $12.07 billion a year earlier. Analysts surveyed by Capital IQ...
Atmus Filtration Technologies' Q3 Adjusted Earnings, Net Sales Rise; 2024 Guidance Revised
Atmus Filtration Technologies' Q3 Adjusted Earnings, Net Sales Rise; 2024 Guidance Revised
Nov 8, 2024
06:56 AM EST, 11/08/2024 (MT Newswires) -- Atmus Filtration Technologies ( ATMU ) reported Q3 adjusted earnings Friday of $0.61 per share, up from $0.52 a year earlier. Analysts polled by Capital IQ expected $0.52. Net sales for the quarter ended Sept. 30 were $403.7 million, up from $396.2 million a year earlier. Analysts surveyed by Capital IQ expected $403.4...
Multiple Port Shutdowns Leave Canada's Small Firms in The Cold, Says CFIB
Multiple Port Shutdowns Leave Canada's Small Firms in The Cold, Says CFIB
Nov 8, 2024
08:06 AM EST, 11/08/2024 (MT Newswires) -- The simultaneous work stoppages at Canada's three largest ports are damaging many small businesses and costing the country's economy hundreds of millions every day, said the Canadian Federation of Independent Business (CFIB) on Friday. The current shutdowns at the Port of Montreal and British Columbia ports cannot drag on any longer, stated CFIB....
Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance
Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance
Nov 8, 2024
12:19 PM EST, 11/05/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday that its lead drug candidate Reqorsa demonstrated positive results in a preclinical study in mice. In one mice group that was supplemented with the Reqorsa gene therapy, Genprex ( GNPX ) said tumor growth was diminished and there was a significant reduction in T reg as well...
Copyright 2023-2026 - www.financetom.com All Rights Reserved